Form 4: Coherus BioSciences Director Acquires Stock Options

Director Jill O'Donnell-Tormey acquired stock options for 112,000 shares of Coherus BioSciences common stock on June 3, 2024.

Summary

• On June 3, 2024, Jill O'Donnell-Tormey, a director of Coherus BioSciences, Inc., acquired stock options for 112,000 shares.
• The exercise price of these options is $1.76 per share.
• The options vest and become exercisable on June 3, 2025, one year after the grant date, contingent upon continued service with the company.
• The options expire on June 3, 2034.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The acquisition of stock options by a director suggests confidence in the company's future, but it's a routine transaction.

Positives

• A director's acquisition of stock options can be seen as a positive signal, indicating confidence in the company's future performance.

Future Outlook

The vesting of the options is contingent upon the director's continued service with the company, aligning her interests with the long-term success of Coherus BioSciences.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to incentivize performance and align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in the biotechnology industry.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options as part of their executive compensation plans.
• The vesting schedules and exercise prices are typically structured to incentivize long-term value creation.

Key Dates